ReviewFuture oncology (London, England)2025

The value of real-world evidence in supporting targeted therapies for patients with rare oncogenic drivers in mNSCLC.

Misako Nagasaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.